An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
University of Chicago
Medical University of South Carolina
Dana-Farber Cancer Institute
Thomas Jefferson University
NRG Oncology
Columbia University
M.D. Anderson Cancer Center
Thomas Jefferson University
Alliance for Clinical Trials in Oncology
UNC Lineberger Comprehensive Cancer Center
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vanderbilt-Ingram Cancer Center
Xinqiao Hospital of Chongqing
Dartmouth-Hitchcock Medical Center
Canadian Cancer Trials Group
Baylor College of Medicine
University of Arizona
Rutgers, The State University of New Jersey
Columbia University
NYU Langone Health
Rush University Medical Center
Fox Chase Cancer Center
Pennington Biomedical Research Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
GOG Foundation
Case Comprehensive Cancer Center
Ozmosis Research Inc.
Woman's
National Institutes of Health Clinical Center (CC)
University of Virginia
Northwestern University
M.D. Anderson Cancer Center
University of Cincinnati
University of California, San Diego
Mayo Clinic
Khyber Medical University Peshawar
M.D. Anderson Cancer Center
Avera McKennan Hospital & University Health Center
National Cancer Institute (NCI)
Northwestern University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
University of Michigan Rogel Cancer Center
The University of Texas Health Science Center at San Antonio
Beth Israel Medical Center
Milton S. Hershey Medical Center
National Cancer Institute (NCI)